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CLINICAL SCIENCE
HIV-1 Drug Resistance Among Ugandan Adults Attending
an Urban Out-Patient Clinic
Amrei von Braun, MD,*† Christine Sekaggya-Wiltshire, MD,* Nadine Bachmann,†‡
Deogratius Ssemwanga, PhD,§ Alexandra U. Scherrer, PhD,†‡ Maria Nanyonjo,§ Anne Kapaata,§
Pontiano Kaleebu,§ Huldrych F. Günthard,†‡ Barbara Castelnuovo, MD, PhD,* Jan Fehr,†k and
Andrew Kambugu, MD*
Background: Little is known about prevalence of drug resistance
among HIV-infected Ugandans, a setting with over 15 years of
public sector access to antiretroviral therapy (ART) and where
virological monitoring was only recently introduced.
Setting: This study was conducted in the adults’ out-patient clinic
of the Infectious Diseases Institute, Kampala, Uganda.
Methods: HIV genotyping was performed in ART-naive patients
and in treatment-experienced patients on ART for $6 months with
virological failure ($1000 copies/mL).
Results: A total of 152 ART-naive and 2430 ART-experienced
patients were included. Transmitted drug resistance was detected in 9
(5.9%) patients. After a median time on ART of 4.7 years
[interquartile range: 2.5–8.7], 190 patients (7.8%) had virological
failure with a median viral load of 4.4 log10 copies per milliliter
(interquartile range: 3.9–4.9). In addition, 146 patients had a viral
load between 51 and 999 copies per milliliter. Most patients with
virological failure (142, 74.7%) were on ﬁrst-line ART. For 163
(85.8%) ART-experienced patients, genotype results were available.
Relevant drug-resistance mutations were observed in 135 (82.8%),
of which 103 (63.2%) had resistance to 2 drug classes, and 11 (6.7%)
had resistance to all drug classes available in Uganda.
Conclusion: The prevalence of transmitted drug resistance was lower
than recently reported by the WHO. With 92% of all patients
virologically suppressed on ART, the prevalence of virological failure
was low when a cutoff of 1000 copies per milliliter is applied, and is in
line with the third of the 90-90-90 UNAIDS targets. However, most
failing patients had developed multiclass drug resistance.
Key Words: HIV drug resistance, virological failure, Uganda,
treatment monitoring
(J Acquir Immune Deﬁc Syndr 2018;78:566–573)
INTRODUCTION
In Uganda, antiretroviral therapy (ART) was ﬁrst made
available for selected HIV-infected patients through the
private sector and small pilot research studies in 1998,
approximately 5 years earlier than in other countries in sub-
Saharan Africa.1 When low-cost, high-quality generic anti-
retroviral drugs became available in 2001, the Ugandan
government introduced ART for HIV-infected patients with
advanced HIV disease funded by the World Bank Multi-
Sectoral AIDS Project (MAP).2,3 Since 2003, ART in Uganda
is largely funded by the US President’s Emergency Plan for
HIV/AIDS Relief (PEPFAR) and has been made available to
a large part of HIV-infected Ugandans based on existing
national guidelines.4 According to the Ugandan Population
HIV Impact Assessment (UPHIA), 1.3 million people in
Uganda were living with HIV in 2016 (prevalence 6.2%
among adults), and the ART coverage was 60%.5
In line with WHO guidelines, ﬁrst-line treatment regimens
in Uganda consist of a ﬁxed-dose combination of 2 nucleoside
reverse transcriptase inhibitors (NRTIs), either AZT/3TC or
TDF/3TC, with 1 nonnucleoside reverse transcriptase inhibitor
(NNRTI), either nevirapine or efavirenz.4 Second-line treatment
options are reserved for patients failing ﬁrst-line treatment and
consist of a protease inhibitor (PI) with 2 NRTIs. Integrase
inhibitors such as raltegravir or dolutegravir are considered third-
line drugs and were only available through research studies or
private purchase at the time of study implementation.
Previous studies on the prevalence of transmitted drug
resistance in Uganda mainly focused on key populations or
had small patient numbers. For instance, a study from 2004
included 81 patients from Kampala and found a prevalence of
transmitted drug resistance of 7%.6 A more recent, but
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similarly small study examined transmitted drug resistance
among Ugandan ﬁshing communities, which is a high-risk
group around Lake Victoria, and found resistance to NNRTI
in 3 of 47 (6.4%) treatment-naive patients.7
As resistance mutations impact therapeutic outcomes,
in developed countries, genotypic resistance testing is rec-
ommended before starting treatment and before considering
a switch of regimen.8 However, genotypic resistance testing
remains costly and is therefore reserved for research or
privately paid for in resource-limited countries including
Uganda. A meta-analysis has shown a higher prevalence of
HIV drug resistance among ART-naive patients in East Africa
compared with other regions with a 29% increase of HIV
drug resistance per year since the ART roll out, compared
with lower rates in Southern Africa (14%) and Central and
West Africa (3%).9 Because of growing evidence of increas-
ing resistance to ART, there is need for further documentation
of the current state of both acquired and transmitted drug
resistance in Uganda.10–12 The objective of our study was to
report the type and frequency of HIV drug resistance among
ART-naive, as well as ART-experienced urban Ugandan
adults by performing a cross-sectional study in one of the
largest HIV treatment centers in Kampala.
METHODS
Setting
We conducted a cross-sectional study at the adult clinic
of the Infectious Diseases Institute (IDI), College of Health
Sciences, Makerere University in Kampala, Uganda, between
June 4 and September 30, 2015. The IDI is a center of
excellence for HIV treatment located at the national referral
hospital complex, and currently cares for over 8000 registered
patients infected with HIV.13 Up to December 2014, patients
on ART were monitored with CD4 count measurements every
6 months, whereas viral load testing was made available only
for patients who were thought to have treatment failure based
on immunological or clinical criteria.14
All HIV-infected patients presenting at the IDI during
the study period, who were 18 years or older, ART-naive or
on ART for $6 months, and due for a CD4 cell count
measurement were eligible for study participation. As deﬁned
by the WHO,15 transmitted HIV drug resistance is detected in
ART-naive people with no history of antiretroviral drug
exposure. Therefore, all patients currently without ART but
previous exposure to ART, such as women with a history of
treatment for the prevention-of-mother-to-child-transmission
(PMTCT), were excluded. Patients with a history of any
blinded ART regimen in the context of clinical trials were
excluded as well. Patients were consecutively screened and
enrolled by trained study staff.
Study Procedures
For each participant, we collected information on demo-
graphics, social and educational background, ART history,
concomitant medication including herbal remedies, alcohol and
recreational drug use, information on adherence by self-report,
side effects, past CD4 cell counts, and, if applicable, past viral
load results. Results for viral loads and genotypic resistance
testing were collected prospectively. Venous blood was drawn
from patients on ART for viral load measurement and plasma
storage at 280°C. CD4 cell counts (BD FACSCalibur Flow
Cytometer: 4-Color) and viral load measurements (COBAS
AmpliPrep/COBAS TaqMan HIV-1 Test, v2.0, Roche Diag-
nostics, cutoff 20 copies per milliliter) were performed at the
Makerere-University-John-Hopkins-University (MUJHU) CORE
laboratory certiﬁed by the College of American Pathologists. For
ART-naive patients, blood was sampled for plasma storage only.
Genotyping was requested at the MRC/UVRI Uganda Research
Unit on AIDS, HIV Drug Resistance Reference Laboratory for
all ART-naive patients and ART-experienced patients with
virological failure, deﬁned as viral load $1000 copies per
milliliter. As previously described, viral RNA was extracted from
140 ml of plasma using the QIAmp Viral RNA mini kit (Qiagen),
the entire protease (codons 1–99) and amino terminus of reverse
transcriptase (codons 1–320) were ampliﬁed and sequenced
using the ABI 3500 machine (Applied Biosystems).12 Sequences
were base-called using Sequencher v5.2.4, and drug resistance
mutations (DRMs) were analyzed using the Stanford HIVdb
Program (https://hivdb.stanford.edu/hivdb/by-mutations). The as-
signed DRMs were interpreted using the 2009 WHO list for
epidemiological surveys. HIV-1 subtyping was performed using
SCUEAL (http://www.datamonkey.org/dataupload_scueal.php)
and REGA (www.bioafrica.net/rega-genotype/html/
subtypinghiv.html) online software. Basic phylogenies were
performed to determine sequence relatedness and to rule out
contaminations. Viral sequences are available in Genbank
accession numbers MF565526–MF565688.
Data Management and Statistical Analysis
Data were collected from patient interview, extracted
from the electronic medical record (Integrated Clinic Enter-
prise Application, ICEA)16 or paper ﬁle and entered into
DataFax forms specially designed for this study. The data
management system DataFax is designated to manage paper
data forms. The forms are faxed to the DataFax server where
they are read using intelligent characters-recognition and
populate the study database.
Univariate and multivariate logistic regressions were
performed to identify risk factors for virological failure in
patients on ﬁrst- and second-line ART. The following
potential risk factors or correlates for virological failure were
considered in the univariate analysis: age, sex, current ART
regimen, years on ART, CD4 cell count, number of children,
marital status, adherence to ART, reported side effects, and
previous viral load measurements. For the subsequent
multivariate analysis, we selected all variables with a P value
, 0.1 in the univariate model, checked for multicollinearity,
and in case of multicollinearity selected according to
clinical relevance.
Ethical Considerations
This study was reviewed and approved by the Makerere
University School of Biomedical Research and Ethics
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Committee (SBS254), and the Uganda National Council for
Science and Technology (HS 1800). The study was registered
on ClinicalTrials.gov (NCT02507921). Written informed
consent was obtained from all participants before enrollment.
The funders had no role in study design, data collection, data
analysis, data interpretation, or writing of the manuscript.
RESULTS
A total of 2808 participants were enrolled in the study
consisting of 220 ART naive and 2588 ART experienced,
respectively. Figure 1 depicts the disposition of patients from
screening to enrollment.
ART-Naive Patients
After withdrawing 14 patients with a history of
PMTCT, 206 ART-naive patients were included. The median
age was 33 years (IQR: 26–41), and most patients had WHO
disease stage 1 (84, 40.8%) or 2 (76, 36.9%). The median
CD4 cell count was 511 cells/mL (IQR: 284–713). A total of
91 (44.2%) were either married or cohabitating, of which 59
(64.8%) reported to have an HIV-infected partner. The
majority of the partners (54, 91.5%) were already on ART.
Fourteen patients (6.8%) reported to have HIV-
infected children.
Drug-resistance testing could be performed in 152
ART-naive patients. Mutations associated with HIV drug
resistance were found in 9/152 (5.9%) patients. Five patients
(5/152, 3.3%) had any NRTI mutation (K65R: 1, M184V: 2,
and other: 2), and 8/152 (5.3%) had any NNRTI mutation
(K101E: 3, Y181C: 2, and K103N: 2, other: 4). No major PI
mutation was detected.
ART-Experienced Patients
After withdrawing 158 patients, 2430 ART-experienced
patients were included in this study, of which 1526 (62.8%)
were female. Patients were withdrawn for the following
reasons: history of blinded ART regimen (n = 140), current
ART regimen ,6 months (n = 12), and unwillingness to give
a blood sample (n = 6). Overall, study participants had been
on ART for a median time of 4.7 years (IQR: 2.5–8.7 years).
A total of 190 (7.6%) participants had virological failure with
a median viral load of 4.4 log10 copies per milliliter (IQR:
3.9–4.9 log10 copies per milliliter). The majority of patients
with virological failure were female (131/190, 69.0%) and on
ﬁrst-line ART (142/190, 74.7%). Table 1 shows baseline
characteristics of study participants with virological suppres-
sion, as well as virological failure disaggregated by subjects
failing ﬁrst- and second-line ART regimens.
Risk factors for virological failure in patients failing
ﬁrst- and second-line ART were evaluated by univariate and
multivariate analyses. As shown in Figure 2 for all patients,
virological failure was signiﬁcantly more likely in patients on
second-line ART [adjusted odds ratio (aOR): 2.95, 95%
conﬁdence interval (95% CI): 1.87–4.65]. Furthermore, being
separated from the spouse (aOR: 1.86, 95% CI: 1.12–3.01)
and reported side effects (aOR: 1.94, 95% CI: 1.18–3.19)
were associated with virological failure. Previous viral load
measurements (aOR: 0.55, 95% CI: 0.37–0.83), as well as
excellent adherence (aOR: 0.41, 95% CI: 0.24–0.71) were
protective of virological failure. Results of the univariate and
multivariate analysis were further disaggregated by patients
failing on ﬁrst- and second-line ART. For patients on ﬁrst-line
ART (Table 2A), reported side effects (aOR: 2.01, 95% CI:
1.17–3.46), as well as living separated from the spouse (aOR:
2.21, 95% CI: 1.29–3.81) were strongly associated with
virological failure. Excellent adherence was protective of
virological failure (aOR: 0.33, 95% CI: 0.18–0.61). In our
study population, virological failure was signiﬁcantly more
likely to occur in patients on second-line treatment. In these
patients (Table 2B), virological failure was associated with
being single or separated from the spouse (aOR: 1.46, 95%
CI: 0.55–3.92). A low CD4 cell count was not associated with
virological failure. However, this may be due to a small
sample size of patients failing on second-line treatment (N =
48). Previous viral load measurements (aOR: 0.21, 95% CI:
0.09–0.52) were strongly protective of virological failure in
patients on second-line ART.
Of 190 patients with a viral load .1000 copies per
milliliter, HIV genotyping tests were available from 163
FIGURE 1. Enrollment process.
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(85.8%) cases. HIV subtypes A (47.2%) and D (34.4%) were
most common, 16.0% were recombinants. Subtypes C (1.8%)
and G (0.6%) were rarely seen. Relevant DRMs were
observed in 135 (82.8%), of which 103 (63.2%) had
resistance to 2 drug classes, and 11 (6.7%) had resistance to
all 3 drug classes available in Uganda. PI mutations were
observed in 13 (8.0%) patients. Any NRTI mutation was
found in 122 (74.8%) patients, most commonly M184V
(65.0%). A total of 125 (76.7%) patients had any NNRTI
mutation, most commonly K103N (42.9%). Of the 163
patients with available resistance testing, 28 (17.2%) had
a K65R mutation. Almost all these patients were currently on
treatment with tenofovir (22/28, 78.6%). Figure 3A, B show
the resistance mutations found in patients failing ﬁrst- and
second-line ART with available sequence data.
In this study, resistance testing was performed only in
patients with a viral load .1000 copies per milliliter. A viral
load between 51 and 500 copies per milliliter was detected in
127 (5.1%) participants (median viral load 130 copies per
milliliter, IQR: 82–201 copies per milliliter), whereas 19
(0.8%) study participants had a viral load between 501 and
999 copies per milliliter (median viral load 623 copies per
milliliter, IQR: 565–797 copies per milliliter). Thus, if a cutoff
of 50 copies per milliliter is applied, as is the case in resource-
rich settings, the rate of virological failure almost doubles to
345 patients (13.4%).
DISCUSSION
Our study indicates a low level of transmitted HIV drug
resistance in this large urban HIV treatment center in a setting
with public sector ART access for more than one and a half
decades. Given the paucity of published HIV drug resistance
studies in ART-naive individuals in the region, our ﬁndings
provide some insight on the level of transmitted drug
resistance for similar settings in the region. In addition, our
study found a high rate of virological suppression. With over
92% of all patients virologically suppressed on ART, the
overall prevalence of virological failure was low in our study
population, and this is in line with the third of the 90-90-9017
UNAIDS targets. However, most failing patients had devel-
oped multiclass drug resistance.
Transmitted Drug Resistance
Although there are limited data available on acquired
resistance in Uganda, there is even less on transmitted drug
resistance among HIV-infected Ugandans.12 We found a pro-
portion of 5.9% among our study population, which accord-
ing to the WHO grading system is the cutoff between low
(,5%) and moderate (5%–15%). Despite over 10 years of
widespread ART availability in Uganda, according to this
ﬁnding, the prevalence of transmitted drug resistance in adults
seeking care in our clinic seems to be low. Furthermore,
mutations to PI, which are commonly used as second-line
treatment options, were not observed. These ﬁndings are in
line with previous studies from Uganda, which showed low
rates of transmitted drug resistance in rural areas, as well as in
urban settings 10 years after the introduction of ART.6,18
The most recent report on HIV drug resistance
published by the WHO found a high proportion of patients
with pretreatment drug resistance in Uganda.15 According to
the WHO deﬁnition, pretreatment drug resistance is detected
in treatment-naive people initiating ART or people with
previous antiretroviral drug exposure initiating or reinitiating
ﬁrst-line ART. Thus, pretreatment drug resistance includes
transmitted drug resistance but can be acquired as well. The
data on pretreatment drug resistance from Uganda included
342 adults (203 women, 65.4%), of which 296 (78.7%) had
no previous exposure to ART. According to the report, levels
of NNRTI pretreatment drug resistance were greater than
10% in 3 of 4 countries in the African region, ranging from
8.1% (95% CI: 4.3–14.7) in Cameroon to 15.4% (95% CI:
10.3–22.5) in Uganda. Any transmitted DRM was found in
18.1% (95% CI: 12.7–25.2) of Ugandan patients. Compared
with the WHO report, our ﬁndings on transmitted drug
resistance are much lower. Generally, surveillance data can
be heterogeneous. The WHO report used a nationally repre-
sentative sampling method described in detail in the report as
TABLE 1. Baseline Characteristics of Patients With and
Without Virological Failure
Characteristics
Not Failing Failing First Line
Failing
Second Line
N = 2240 N = 142 N = 48
Female sex (N, %) 1395 (62.3) 102 (71.8) 29 (60.4)
Median age in yr
(IQR)
42 (35–49) 35 (28–42) 41 (35.8–45.5)
WHO disease stage
(N, %)
1, 2 806 (36.0) 60 (42.3) 11 (23.0)
3, 4 1434 (64.0) 82 (57.7) 37 (77.0)
Median CD4 cell
count in cells/ml
(IQR)
Current 491 (350–657) 254 (106.2–404.2) 325 (200–453)
Nadir 129 (44–235) 126.5 (43–202.8) 43.5 (9–106.5)
Median time on ART
in yr (IQR)
5.2 (2.8–9.4) 3.3 (1.8–5.1) 6.1 (4.3–9.9)
Current ART regimen
(N, %)
First-line NNRTI
based
1932 (86.3) 142 (100) 0
TDF + XTC + NVP 138 16 (11.3) 0
TDF + XTC + EFV 712 54 (38.0) 0
ZDV + XTC + NVP 624 47 (33.1) 0
ZDV + XTC + EFV 436 24 (16.9) 0
ZDV + 3 TC + TDF 7 1 (0.7) 0
D4T + XTC + NVP 3 0 0
ABC + XTC + EFV 7 0 0
ABC + XTC + NVP 5 0 0
Second-line PI
based
308 (13.7) 0 48 (100)
ATV/r 86 0 16 (33.3)
LPV/r 222 0 32 (66.6)
ATV/r, ritonavir-boosted atazanavir; EFV, efavirenz; LPV/r, ritonavir-boosted
lopinavir; NVP, nevirapine; TDF, tenofovir; XTC, FTC or 3TC; ZDV, zidovudine.
J Acquir Immune Defic Syndr  Volume 78, Number 5, August 15, 2018 HIV Drug Resistance Among Ugandan Adults
Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. www.jaids.com | 569
 
opposed to site-speciﬁc data. Second, considerable ﬂuctua-
tions over time have been observed in other countries, which
can so far only partly be explained. One reason for these
ﬂuctuations was the introduction of new drugs as seen for
boosted PIs in Switzerland.19 We conclude that more data are
needed to complete the picture.
Virological Failure
Our study found a high rate of virological suppression.
Using a cutoff for virological failure of 1000 copies per
milliliter, over 92% of all patients were suppressed on ART,
which is in line with the third of the 90-90-90 UNAIDS
targets.17 This is especially encouraging because for several
years, these patients were monitored using CD4 cell measure-
ments only. Optimal adherence, high-quality clinical man-
agement, and consistent drug supplies probably contributed to
these outcomes. The high proportion of patients virologically
suppressed on ﬁrst-line treatment is in line with ﬁndings from
other studies previously conducted at the IDI.20 To maintain
a high rate of virological suppression, the clinic adopted
several differentiated care models, such as the nurse-visit or
pharmacy-reﬁll program.21 In both models, task shifting
enables clinicians to concentrate on challenging cases. As
the IDI is a center of excellence for HIV care, our study
ﬁndings cannot be generalized. This aspect becomes even
more apparent if our results are compared with the data
provided by the UPHIA, which reports a prevalence of
virological suppression among all HIV-positive Ugandan
adults aged 15 to 64 years of only 59.6% (62.9% among
females and 53.6% among males).5 However, the results of
our study demonstrate how well patients can do within an
optimal setting.
Nevertheless, it is notable that the proportion of patients
with virological failure doubles if a cutoff of 50 copies per
milliliter is applied, as is standard in many resource-rich
settings. In our study, 146 patients had a viral load between
51 and 999 copies per milliliter. Using a cutoff of 1000 copies
per milliliter for treatment failure makes sense in the context
of “treatment as prevention,” as it is well described that
transmission practically does not take place below this cutoff.
However, the development of HIV drug resistance among
patients with low-level viremia may be underestimated. In
fact, a recent nationwide study from France found that 48.5%
of samples from patients with a viral load between 51 and 200
copies per milliliter harbored resistance mutations.22 Further-
more, recently published data from a South African cohort
study that included over 70,000 HIV-positive patients from
57 clinical sites identiﬁed low-level viremia (deﬁned as a viral
FIGURE 2. Univariate and multivariate analysis of risk factors for virological failure. cART, combination antiretroviral therapy.
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load of 51–999 copies per milliliter) in 23% of patients on
ﬁrst-line treatment. According to the authors, low-level
viremia was associated with increased hazards of virological
failure (hazard ratio 2$6, 95% CI: 2$5–2$8; P , 0$0001) and
switch to second-line ART (hazard ratio 5$2, 4$4–6$1; P ,
0$0001]) compared with virological suppression of less than
50 copies per milliliter.23 These ﬁndings challenge the deﬁ-
nition of therapeutic failure in guidelines using a cutoff of
1000 copies per milliliter, and evidence suggests that strate-
gies for the management of low-level viremia need to be
incorporated into international guidelines to meet UNAIDS-
deﬁned targets.
Acquired Drug Resistance
The high proportion of virological suppression on ART
is encouraging. However, most study participants with
virological failure had developed resistance to more than 1
drug class, suggesting that failing regimens not identiﬁed by
CD4 cell count monitoring in a timely fashion had been in
place for a prolonged period. This study ﬁnding is most
worrisome, as efﬁcacious treatment options are limited for
TABLE 2. Univariate and Multivariate Analyses of Risk Factors
for Virological Failure in A) Patients on First-Line ART and B)
Patients On Second-Line ART
Variable
Univariate Analysis Multivariate Analysis
OR 95% CI P OR 95% CI P
A) Patients on First-
Line ART
Age 0.12 0.06.0 to
24
,0.001 0.07 0.02 to
0.22
,0.001
Male sex 0.74 0.54 to
1.03
0.08 0.44 0.27 to
0.71
,0.001
CD4 cell count in
cells/ml
,200 (reference)
200–350 0.07 0.04 to
0.12
,0.001 0.04 0.02 to
0.09
,0.001
351–500 0.12 0.07 to
0.17
,0.001 0.08 0.04 to
0.14
,0.001
501–650 0.23 0.15 to
0.35
,0.001 0.19 0.11 to
0.32
,0.001
.650 0.04 0.02 to
0.08
,0.001 0.02 0.01 to
0.06
,0.001
Previous viral load 0.62 0.44 to
0.86
0.005 0.64 0.41 to
0.99
0.05
Missed pills
.1/mo
(reference)
Never 0.31 0.2 to
0.48
,0.001 0.33 0.18 to
0.61
,0.001
1/mo 0.66 0.39 to
1.1
0.11 0.79 0.4 to
1.55
0.49
Side effects 2.16 1.43 to
3.25
,0.001 2.01 1.17 to
3.46
0.01
Marital status
Married
(reference)
Single 2.19 1.45 to
3.31
,0.001 0.98 0.54 to
1.78
0.95
Separated 1.95 1.29 to
2.96
0.002 2.21 1.29 to
3.81
0.004
Widowed 1.01 0.61 to
1.68
0.98 1.36 0.68 to
2.76
0.39
Cohabitating 1.35 0.72 to
2.51
0.35 1.43 0.65 to
3.14
0.38
No. of children
0–3 (reference)
.3 0.70 0.5 to
0.96
0.03 1.45 0.89 to
2.35
0.14
TABLE 2. (Continued ) Univariate and Multivariate Analyses of
Risk Factors for Virological Failure in A) Patients on First-Line
ART and B) Patients On Second-Line ART
Variable
Univariate Analysis Multivariate Analysis
OR 95% CI P OR 95% CI P
B) Patients on Second-
Line ART
Age 0.12 0.06 to
2.97
0.39 0.43 0.06 to
2.97
0.39
Male sex 0.74 0.54 to
1.03
0.08 0.81 0.35 to
1.87
0.62
CD4 cell count in
cells/ml
,200 (reference) (0.04 to
0.12)
200–350 0.07 (0.07 to
0.17)
,0.001 0.27 (0.07 to
1.03)
0.06
351–500 0.11 (0.15 to
0.35)
,0.001 0.60 (0.19 to
1.86)
0.37
501–650 0.23 (0.02 to
0.08)
,0.001 0.70 (0.23 to
2.13)
0.53
.650 0.04 ,0.001 0.10 (0.03 to
0.41)
0.001
Previous viral load 0.62 (0.44 to
0.86)
0.01 0.21 (0.09 to
0.52)
,0.001
Missed pills
. 1/mo
(reference)
Never 0.31 (0.2 to
0.48)
,0.001 1.11 (0.34 to
3.58)
0.87
1/mo 0.66 (0.39 to
1.1)
0.11 1.28 (0.31 to
5.23)
0.73
Side effects 2.18 (1.43 to
3.25)
,0.001 1.34 (0.39 to
4.55)
0.64
Marital status
Married
(reference)
Single 2.19 (1.45 to
3.31)
,0.001 1.46 (0.55 to
3.92)
0.45
Separated 1.95 (1.29 to
2.96)
0.001 0.81 (0.27 to
2.47)
0.71
Widowed 1.01 (0.61 to
1.68)
0.98 0.64 (0.19 to
2.17)
0.47
Cohabitating 1.35 (0.72 to
2.51)
0.35 0.80 (0.15 to
4.14)
0.80
No. of children
0–3 (reference)
.3 0.70 (0.5 to
0.96)
0.03 1.36 (0.59 to
3.11)
0.47
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patients with multiclass drug resistance in this setting, which
puts these patients at high risk of disease progression and
transmission of resistant virus strains. The accumulation of
DRMs over time in patients with continued virological failure
was shown in previously conducted studies from Uganda and
other sub-Saharan African countries.24,25 A systematic review
and meta-analysis that included 8376 patients from 8 cohorts
and 2 prospective studies showed a signiﬁcantly higher
proportion of resistance mutations at virological failure in
patients monitored less frequently.26 This is in line with our
observation that previous viral load measurements were
protective of virological failure and thus the development of
resistance mutations in patients on second-line ART.
The distribution of mutations found in our study is
largely in line with ﬁndings from other studies conducted in
the region. A systematic review of 89 studies with 13,288
patients from sub-Saharan Africa found the prevalence of
viral suppression at 12 months to be 76%.27 In patients with
virological failure, the most common resistance mutations
reported by the authors were M184V (65%) and K103N
(52%), whereas thymidine analog mutations (TAMs) and
K65R were much less common (5%–20%). The PharmAccess
African Studies to Evaluate Resistance (PASER), which
evaluated data from 6 African countries, found that 8.5% of
patients with virological failure after 11–15 months of ART
have more than 1 TAM.28
Among the 163 patients with available resistance data
in our study, 54 (33.1%) were on TDF-containing regimens.
Of these, 22 (40.7%) had a K65R mutation compared with
only 28 (17.8%) among the entire study population. A recent
study on the global epidemiology of HIV drug resistance after
failure of WHO recommended ﬁrst-line regimens was
recently published.29 In low- and middle-income countries,
the authors found drug resistance in a high proportion of
patients failing treatment with tenofovir-containing regimens.
Tenofovir resistance was highest in sub-Saharan Africa (370/
654, 57%). The study ﬁndings reported here, as well as
observations from other studies on emergence of resistance in
the region stress the need for enhanced surveillance and
preventive measures.30,31
Our study has a few limitations. For one, women
currently without ART but with a history of PMTCT (WHO
option B) were excluded from participation. These women
were excluded because they did not fulﬁll the criteria of being
ART naive or on a stable regimen for at least 6 months.
However, HIV drug resistance today plays an important role
in these women, and further research focused speciﬁcally on
this group is needed. A further limitation is that we failed to
collect information on pregnancy, as well as on tuberculosis
coinfection. Both aspects are relevant in the context of
treatment failure and should have been taken into account.
Furthermore, a number of resistance tests failed. We were
unable to ascertain the cause of failure to genotype 54
samples of ART-naive and 36 samples of ART-experienced
participants. Although this did not result in a selection bias, it
reduced the number of available tests for this study analysis.
However, the number of failed test seems to be in line with
other studies.22
We conclude that the UNAIDS goal of 90% virological
suppression on ART is achievable within an optimal treat-
ment setting. However, if treatment failure occurred, a high
proportion had developed multiclass drug resistance, which
massively complicates sufﬁcient treatment in this setting.
Furthermore, if a cutoff for treatment failure of 50 copies per
milliliter is applied, the rate of patients with virological failure
doubles and most likely resistance among these patients is
underestimated. As ART scale-up continues in the region,
close surveillance of HIV drug resistance—both acquired and
transmitted—is essential to assess optimal treatment regimens
available to patients, and thereby prevent the further emer-
gence and spread of resistant strains.
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